Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | ITGAL | P20701 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9544373 | 0.98 | GAA (0.56) | GAAMAPTITGB3ITGB2ITGB1 | |
| SCHEMBL18707926 | 0.85 | GAA (0.51) | GAAMAPTMTNR1ACREBBPMTNR1B | |
| SCHEMBL7654395 | 0.85 | GAA (0.51) | GAAMAPTITGB3ITGB2ITGB1 | |
| SCHEMBL3123562 | 0.85 | GAA (0.51) | GAAMAPTEGFRMTNR1ACREBBP | |
| SCHEMBL7416734 | 0.85 | GAA (0.51) | GAAMAPTMTNR1ACREBBPMTNR1B | |
| SCHEMBL5036112 | 0.82 | GAA (0.49) | GAAMAPTITGB3ITGB2ITGB1 | |
| SCHEMBL7488882 | 0.81 | GAA (0.44) | GAAMAPTITGB3ITGB2ITGB1 | |
| SCHEMBL8905113 | 0.81 | EGFR (0.49) | GAAMAPTEGFRMTNR1ACREBBP | |
| SCHEMBL5547311 | 0.81 | GAA (0.46) | GAAMAPTMTNR1ACREBBPMTNR1B | |
| SCHEMBL27719438 | 0.81 | MAPT (0.48) | GAAMAPTITGB3ITGB2ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| WO-2008078350-A2 | PROCESS FOR THE PREPARATION OF FLUOROPHENYLACETIC ACIDS AND DERIVATIVES THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2008-07-03 | — | — | WO | disclosed |
| CN-1289499-C | Pyrazino (aza) indole derivatives | VERNALIS RES LTD (GB) | 2006-12-13 | — | — | CN | disclosed |
| CN-1837207-A | Pirazino(aza)indole derivatives | VERNALIS RES LTD (GB) | 2006-09-27 | — | — | CN | disclosed |
| CN-1337963-A | Pyrazino (aza) indole derivatives | VERNALIS RES LTD (GB) | 2002-02-27 | — | — | CN | disclosed |
| CN-1156995-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-08-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | GAA 1992/4885MAPT 4528/4885ITGB3 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.